With a background spanning biochemistry, genetics, and two decades of therapeutic innovation, Nataraj has worked across Alzheimer’s, Parkinson’s, infectious diseases, cardiotoxicity, and genetic disorders. At LigronBio, he is focused on advancing targeted, AI‑driven molecular glue therapies to bring new hope to patients with limited treatment options